WellSky ® Wins ‘Best Home Health Care Solution' Designation in Ninth Annual MedTech Breakthrough Awards Program
OVERLAND PARK, Kan.--(BUSINESS WIRE)-- WellSky, a global health and community care technology and services company, today announced that WellSky Enterprise Referral Manager has been named 'Best Home Health Care Solution' in the ninth annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global digital health and medical technology market. This is the sixth consecutive year that WellSky has been honored by MedTech Breakthrough.
WellSky Enterprise Referral Manager helps agencies transform referral and intake processes, putting them on a path for efficient, effective, and sustainable growth.
The WellSky Enterprise Referral Manager solution transforms referral, intake, and customer relationship management processes for home health, hospice, and other home-based care agencies by consolidating inbound referrals originating from nearly 2,000 hospitals using WellSky CarePort solutions, e-Fax, and direct secure messaging within a single dashboard, centralizing referral activity in one place. The solution surfaces information needed to evaluate referrals, such as payer and insurance details, services requested, discharge date, ZIP code, and more. This allows intake staff members to spend less time clicking between solutions, enabling them to make quicker decisions and respond to referrals faster directly within their workflow.
"Home health and hospice agencies depend on referrals for growth but the process of managing referrals is complicated, with the data within referrals often scattered, forcing intake staff to open several documents, work in multiple systems, and piece together the information to make decisions,' said Steve Johansson, managing director, MedTech Breakthrough. 'WellSky Enterprise Referral Manager helps agencies transform referral and intake processes, putting them on a path for efficient, effective, and sustainable growth. We're pleased to award WellSky with the 'Best Home Health Care Solution' for 2025.'
WellSky Enterprise Referral Manager also supports referral task creation and assignment across intake, sales, and marketing roles, enabling intake coordinators to track the status of required pre-visit activities and begin care in a timely fashion. Additionally, the solution uses patient information received within referrals to create or update patient records within the WellSky electronic health record (EHR), helping to eliminate workflow bottlenecks, prevent duplicate EHR records, and improve intake throughput.
'An agency's ability to quickly respond to referrals is critical to operations, affecting staffing, growth, and high-quality care delivery. Our solution improves the entire referral process with a centralized view, integrated referral data sent into the EHR, and synchronized referral activities between agency roles,' said Bill Miller, chairman and CEO at WellSky. 'We're grateful to MedTech Breakthrough for this recognition and we'll continue to deliver cutting-edge solutions that improve outcomes through efficiency, intelligence, and connection.'
The MedTech Breakthrough Awards program celebrates excellence and innovation in the health and medical technology industry, recognizing the companies and solutions driving meaningful progress and improving patient care. Spanning a wide range of categories—including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records, Virtual Care, Medical Devices, Medical Data & Privacy, and beyond—the awards highlight the groundbreaking work that is transforming the healthcare landscape.
This year, the program received more than 4,500 nominations from leading companies and startups in more than 18 countries, showcasing the global impact and momentum of the digital healthcare industry today.
To learn more about WellSky Enterprise Referral Manager, visit wellsky.com
About WellSky ®
WellSky is one of America's largest and most innovative healthcare technology companies leading the movement for intelligent, coordinated care. Our proven software, analytics, and services power better outcomes and lower costs for stakeholders across the health and community care continuum. In today's value-based care environment, WellSky helps providers, payers, health systems, and community organizations scale processes, improve collaboration for growth, harness the power of data analytics, and achieve better outcomes by further connecting clinical and social care. WellSky serves more than 20,000 client sites — including the largest hospital systems, blood banks, cell therapy labs, home health and hospice franchises, post-acute providers, government agencies, and human services organizations. Informed by more than 40 years of providing software and expertise, WellSky anticipates clients' needs and innovates relentlessly to build healthy, thriving communities. For more information, visit wellsky.com.
About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose. For more information visit MedTechBreakthrough.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Somnics Health Launches iNAP Essentials: Making Innovative OSA Therapy Accessible for $58/Month
REDWOOD CITY, Calif., June 09, 2025--(BUSINESS WIRE)--Somnics Health, a pioneer in next-generation sleep apnea solutions, announces the launch of iNAP Essentials, a breakthrough program giving patients access to iNAP Sleep Therapy for just $58/month over 24 months. This new initiative removes one of the biggest barriers to treatment—cost—and expands access to comfortable, mask-free therapy for patients with Obstructive Sleep Apnea (OSA). More than 50 million Americans suffer from OSA, yet 80% remain untreated, and many who start CPAP therapy abandon it due to discomfort. The iNAP system offers a new path forward. "The OSA treatment landscape is no longer CPAP-only. iNAP is effective, comfortable, and discreet—and now, more affordable than ever," said Olivier Lauzeral, General Manager of Somnics Health. "With iNAP Essentials, we're removing the affordability hurdle." A Smarter, Simpler Solution iNAP is an FDA-cleared, clinically validated therapy that uses gentle negative pressure to keep the airway open during sleep—without forcing air through a mask. It works by creating a light vacuum in the oral cavity, shifting soft tissues forward and preventing obstruction. Key benefits include: No mask, no noise, no forced air Compact and travel-friendly Rechargeable battery lasting up to 5 nights Patients appreciate the freedom and discretion the iNAP system offers, particularly for travel and daily life. "Adherence is one of iNAP's biggest strengths," added Lauzeral. "When therapy fits into your life instead of disrupting it, patients stay with it—and that's how we win against OSA." What's Included in iNAP Essentials For $58/month for 24 months, iNAP Essentials includes: A full iNAP Starter Kit 3 months of supplies (mouthpiece, tubing) Free nationwide shipping Personalized onboarding with a trained iNAP Sleep Coach Access to the iNAP Sleep App for tracking progress and sharing data with providers After the initial supply period, patients can purchase refills as needed from Somnics' online store—offering flexibility without hidden fees or long-term commitments. "We built this program with transparency and simplicity at its core," said Lauzeral. "It's everything you need to start treatment—nothing you don't." Addressing a Changing Market While CPAP has long dominated the OSA space, patient dissatisfaction is driving demand for alternatives like oral appliances, positional therapy, and implantable devices. Many of these, however, are costly, invasive, or hard to access. iNAP stands out as non-invasive, portable, and now financially accessible. Clinical studies show iNAP can significantly reduce AHI, with outcomes on par with CPAP—but with higher comfort and adherence. More Ways to Access iNAP For patients who prefer to own their device upfront, Somnics has partnered with Affirm® to offer interest-free installment plans. "Some patients want to purchase the device outright. With Affirm, they can do that without financial strain," said Lauzeral. Provider-Guided, Patient-Focused iNAP is available by prescription only, ensuring medical oversight from a sleep specialist. Adoption is growing across VA hospitals, sleep centers, and DME providers. "Physicians are seeing the value of iNAP in improving adherence and patient satisfaction," Lauzeral emphasized. "When patients feel empowered, they stay engaged—and that's the future of sleep medicine." Advancing Health Equity Untreated sleep apnea increases the risk of heart disease, stroke, diabetes, and cognitive decline. Somnics Health sees iNAP Essentials not just as a product offering—but as a public health solution. "This isn't just about access—it's about fairness," said Lauzeral. "Sleep apnea is a serious condition, and we believe everyone deserves a shot at better health." About Somnics Health Somnics Health is a medical device company focused on advancing patient-centric solutions for sleep-disordered breathing. Its flagship product, iNAP Sleep Therapy, helps patients treat OSA without the discomfort of traditional therapies. With offices in California and Taiwan, Somnics continues to lead in innovation, education, and patient adherence. Learn More: View source version on Contacts Press Contact: Olivier Lauzeral – olivier@ Follow us on: LinkedIn | Facebook | YouTube Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
3 hours ago
- Business Wire
Securities Fraud Investigation Into Brown-Forman Corporation (BF.A, BF.B) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz announces an investigation of Brown-Forman Corporation ('Brown-Forman' or the 'Company') (NYSE: BF.A, BF.B) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BROWN-FORMAN CORPORATION (BF.A, BF.B), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On June 5, 2025, Brown-Forman reported financial results for its fourth quarter and full year 2025. Amongst other things, the Company reported 'net sales decreased 7% to $894 million,' 'reported operating income decreased 45%,' and 'diluted earnings per share decreased 45%.' The Company stated that 'results did not meet our long-term growth aspirations.' The Company further stated that, in fiscal year 2026, it would 'expect continued headwinds' including declines in organic net sales and operating income, as the Company undergoes a 'significant evolution of [its] U.S. distribution.' On this news, Brown-Forman's stock price fell $5.95, or 17.92%, to close at $27.25 on June 5, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Brown-Forman securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Call us at: 310-914-5007 Email us at: info@ Visit our website at: Follow us for updates on Twitter at If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
4 hours ago
- Yahoo
Afya Limited (the "Company") Notice of Annual General Meeting of the Company
NOVA LIMA, Brazil, June 09, 2025--(BUSINESS WIRE)--Notice is hereby given that an Annual General Meeting of the Company (the "AGM") will be held at the offices of Afya Participações S.A., Alameda Oscar Niemeyer, No. 119, 15th Floor, Vila da Serra, Nova Lima, Minas Gerais, Brazil, Zip Code: 34.006-056, and virtually by accessing the following link (password: afya2025), on the 24th day of June 2025 at 10:00 a.m. BRT, for the purpose of considering and, if thought fit, passing and approving the following resolutions: "As an ordinary resolution, that the Company's financial statements and the auditor's report for the fiscal year ended December 31, 2024 be approved and ratified." "As an ordinary resolution, that João Paulo Seibel de Faria be re-appointed as an independent director of the Company with immediate effect to hold office for a two year term in accordance with the Amended and Restated Articles of Association of the Company." "As an ordinary resolution, that Vanessa Claro Lopes be re-appointed as an independent director of the Company with immediate effect to hold office for a two year term in accordance with the Amended and Restated Articles of Association of the Company." "As an ordinary resolution, that Miguel Filisbino Pereira de Paula be re-appointed as an independent director of the Company with immediate effect to hold office for a two year term in accordance with the Amended and Restated Articles of Association of the Company." "As an ordinary resolution, that Marcelo Ken Suhara be re-appointed as an independent director of the Company with immediate effect to hold office for a two year term in accordance with the Amended and Restated Articles of Association of the Company." The AGM will also serve as an opportunity for shareholders to discuss Company affairs with management. Shareholders may participate in the AGM virtually by accessing the following link (password: afya2025). Participation by a shareholder in the AGM in this manner shall be treated as presence in person at the AGM and such shareholder shall be counted in a quorum and entitled to vote in accordance with Article 18.3 of the Articles of Association of the Company. The Board of Directors of the Company (the "Board") has fixed the close of business, BRT, on May 14, 2025, BRT, as the record date (the "Record Date") for determining the shareholders of the Company entitled to receive notice of the AGM or any adjournment thereof. The holders of record of the Class A common shares and the Class B common shares of the Company as at the close of business, BRT, on the Record Date are entitled to receive notice of and attend the AGM and any adjournment thereof. The Company's 2024 Financial Statements for the fiscal year ended December 31, 2024 was filed with the U.S. Securities and Exchange Commission on March 13, 2025 (the "Financial Statements"). Shareholders may obtain a copy of the Financial Statements, free of charge, from the Company's website at or by contacting the Company's Investor Relations Department by email at ir@ The Board recommends that shareholders of the Company vote "FOR" the resolutions at the AGM. Your vote is very important to the Company. Whether or not you plan to attend the AGM, please promptly complete, date, sign and return the proxy card attached to this Notice. By order of the Board /s/ Kay Kraft__________________ Kay Kraft Director June 9, 2025 Registered Office:c/o Maples Corporate Services LimitedPO Box 309, Ugland HouseGrand CaymanKY1-1104Cayman Islands *A form of proxy has been included with this Notice. NOTES IF YOU HAVE EXECUTED A STANDING PROXY, YOUR STANDING PROXY WILL BE VOTED AS INDICATED IN NOTE 2 BELOW, UNLESS YOU ATTEND THE AGM IN PERSON OR SEND IN A SPECIFIC PROXY. A proxy need not be a shareholder of the Company. A shareholder entitled to attend and vote at the AGM is entitled to appoint one or more proxies to attend and vote in his/her stead. Any standing proxy previously deposited by a shareholder with the Company will be voted in favour of the resolutions to be proposed at the AGM unless revoked prior to the AGM or the shareholder attends the AGM in person or executes a specific proxy. A form of proxy for use at the AGM is enclosed. Whether or not you propose to attend the AGM in person, you are strongly advised to complete and sign the enclosed form of proxy in accordance with the instructions printed on it and then deposit it (together with any power of attorney or other authority under which it is signed or a notarially certified copy of that power or authority) at the offices of Afya Participações S.A., Alameda Oscar Niemeyer, No. 119, 15th Floor, Vila da Serra, Nova Lima, Minas Gerais, Brazil, Zip Code: 34.006-056, or send copies of the foregoing by email to ir@ in each case marked for the attention of Renata Couto, Anibal Sousa and Rodrigo Proença, not later than 11:59 p.m. BRT on the business day prior to the date of the AGM or adjourned AGM in accordance with the Amended and Restated Articles of Association of the Company. Returning the completed form of proxy will not preclude you from attending the AGM and voting in person if you so wish. If two or more persons are jointly registered as holders of a share, the vote of the senior person who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of other joint holders. For this purpose seniority shall be determined by the order in which the names stand on the Company's register of shareholders in respect of the relevant shares. A shareholder holding more than one share entitled to attend and vote at the AGM need not cast the votes in respect of such shares in the same way on any resolution and therefore may vote a share or some or all such shares either for or against a resolution and/or abstain from voting a share or some or all of the shares and, subject to the terms of the instrument appointing any proxy, a proxy appointed under one or more instruments may vote a share or some or all of the shares in respect of which he is appointed either for or against a resolution and/or abstain from voting. No business shall be transacted at the AGM unless a quorum is present at the time when the meeting proceeds to business. One or more Members holding not less than one-third in aggregate of the voting power of all Shares in issue and entitled to vote, present in person or by proxy or, if a corporation or other non-natural Person, by its duly authorised representative, shall represent a quorum. View source version on Contacts Investor Relations Contact:Afya Limitedir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
